Frankfurt - Delayed Quote EUR

BioArctic AB (publ) (B9A.F)

14.93

+0.22

+(1.50%)

As of 8:34:53 AM GMT+2. Market Open.

Key Events

Loading Chart for B9A.F

Previous Close 14.71
Open 14.93
Bid 14.87 x --
Ask 15.23 x --
Day's Range 14.93 - 14.93
52 Week Range 11.94 - 23.10
Volume 405
Avg. Volume 60
Market Cap (intraday) 1.336B
Beta (5Y Monthly) -0.67
PE Ratio (TTM) --
EPS (TTM) -0.18
Earnings Date May 21, 2025
Forward Dividend & Yield --
Ex-Dividend Date May 10, 2019
1y Target Est --

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

www.bioarctic.se

107

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

B9A.F

14.73%

OMX Stockholm 30 Index (^OMX)

5.82%

1-Year Return

B9A.F

16.78%

OMX Stockholm 30 Index (^OMX)

6.71%

3-Year Return

B9A.F

44.25%

OMX Stockholm 30 Index (^OMX)

11.75%

5-Year Return

B9A.F

151.77%

OMX Stockholm 30 Index (^OMX)

52.28%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

BioArctic AB (publ)

14.93

+1.50%

Mkt Cap EUR 1.336B

Industry Biotechnology

Royalty Pharma plc

28.20

0.00%

Mkt Cap EUR 16.364B

Industry Biotechnology

105.50

0.00%

Mkt Cap MXN 25.147B

Industry Biotechnology

Lineage Cell Therapeutics Inc

0.4020

+12.29%

Mkt Cap EUR -

Industry Biotechnology

0.5090

-3.96%

Mkt Cap EUR 29.261M

Industry Biotechnology

Vivoryon Therapeutics NV

1.8260

-0.87%

Mkt Cap EUR -

Industry Biotechnology

Oruka Therapeutics Inc. R

6.65

+3.91%

Mkt Cap EUR -

Industry Biotechnology

Spero Therapeutics, Inc.

0.5290

+6.55%

Mkt Cap EUR 31.745M

Industry Biotechnology

Proteonomix, Inc.

0.0000

-90.00%

Mkt Cap 159,793

Industry Biotechnology

Egetis Therapeutics AB (publ)

0.3100

-5.20%

Mkt Cap EUR 115.963M

Industry Biotechnology

Palatin Technologies Inc

0.1598

-46.64%

Mkt Cap EUR -

Industry Biotechnology

Valuation Measures

    Annual 

As of 4/11/2025

Market Cap

1.32B
Enterprise Value

1.27B
Trailing P/E

--
Forward P/E

11.78
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

56.03
Price/Book (mrq)

16.11
Enterprise Value/Revenue

54.84
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

-68.81%
Return on Assets (ttm)

-12.29%
Return on Equity (ttm)

-18.24%
Revenue (ttm)

257.35M
Net Income Avi to Common (ttm)

-177.08M
Diluted EPS (ttm)

-0.18

Balance Sheet and Cash Flow

Total Cash (mrq)

512.93M
Total Debt/Equity (mrq)

6.06%
Levered Free Cash Flow (ttm)

-558.52M